Evan J. Huppert

Hospital Medicine

500 Harvard St Se
Minneapolis, MN 55455

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

Correction: Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.

Correction: Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.

Journal: Molecular cancer

Published: December 30, 2025

Corrigendum to: "Nuclear EGFR as a molecular target in cancer" [Radiother Oncol 108 (2013) 370-77].

Corrigendum to: "Nuclear EGFR as a molecular target in cancer" [Radiother Oncol 108 (2013) 370-77].

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: October 02, 2018

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.

Journal: Molecular cancer

Published: May 07, 2014

Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.

Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.

Journal: Neoplasia (New York, N.Y.)

Published: September 05, 2013

Nuclear EGFR as a molecular target in cancer.

Nuclear EGFR as a molecular target in cancer.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: April 25, 2013

Showing 1-5 of 5

Last Updated: 09/26/2026